HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 112.5K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Christophe Van Steenkiste, Gontran Verset · The Lancet · 2023 · 679 citations

Medicine, Oncology, Pharmacology +12

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

Minke He, QiJiong Li, Ruhai Zou et al. · JAMA Oncology · 2019 · 548 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23 796 consecutive autopsies

Mats Ögren · World Journal of Gastroenterology · 2006 · 478 citations · Full text

Medicine, Hematology, Pathology +17

Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial

Journal of Clinical Oncology · 2021 · 423 citations

Medicine, Oncology, Pharmacotherapy +15